Rhaeos has developed FlowSense, a clinically validated noninvasive wearable platform technology initially targeting hydrocephalus, a life-threatening condition, caused by an abnormal accumulation of cerebrospinal fluid (CSF) in the brain that affects over 1M Americans today and costs the healthcare system >$2B. With FlowSense, the monitoring of shunt function can occur in clinics, in-patient settings, emergency departments, and homes, with the potential to reduce hospital length of stay and readmission rates.
